Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
Authors: Garrett Nigel , Reddy Tarylee , Yende-Zuma Nonhlanhla , Takalani Azwidhwi , Woeber Kubashni , Bodenstein Annie , Jonas Phumeza , Engelbrecht Imke , Jassat Waasila , Moultrie Harry , Bradshaw Debbie , Seocharan Ishen , Odhiambo Jackline , Khuto Kentse , Richardson Simone I. , Omondi Millicent A. , Nesamari Rofhiwa , Keeton Roanne S. , Riou Catherine , Moyo-Gwete Thandeka , Innes Craig , Zwane Zwelethu , Mngadi Kathy , Brumskine William , Naicker Nivashnee , Potloane Disebo , Badal-Faesen Sharlaa , Innes Steve , Barnabas Shaun , Lombaard Johan , Gill Katherine , Nchabeleng Maphoshane , Snyman Elizma , Petrick Friedrich , Spooner Elizabeth , Naidoo Logashvari , Kalonji Dishiki , Naicker Vimla , Singh Nishanta , Maboa Rebone , Mda Pamela , Malan Daniel , Nana Anusha , Malahleha Mookho , Kotze Philip , Allagappen Jon J. , Diacon Andreas H. , Kruger Gertruida M. , Patel Faeezah , Moore Penny L. , Burgers Wendy A. , Anteyi Kate , Leav Brett , Bekker Linda-Gail , Gray Glenda E , Goga Ameena ,   the SHERPA study team
Published: June 2024

Given limited data on safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income, high-HIV prevalence settings, we evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare workers (HCWs). Sisonke participants were offered mRNA-1273 boosters between May and November 2022, a period of circulating Omicron sub-lineages. Adverse events (AE) were self-reported, and co-primary endpoints (SARS-CoV-2 infections and COVID-19 hospitalizations or deaths) were collected through national databases. We used Cox regression models with booster status as time-varying covariate to determine the relative vaccine effectiveness (rVE) of the mRNA-1273 booster among SHERPA versus unboosted Sisonke participants. Of 11248 SHERPA participants in the rVE analysis cohort (79.3% female, median age 41), 45.4% had received one and 54.6% two Ad26.COV2.S doses. Self-reported comorbidities included HIV (18.7%), hypertension (12.9%) and diabetes (4.6%). In multivariable analysis including 413161 unboosted Sisonke participants, rVE of the booster was 59% (95%CI 29-76%) against SARS-CoV-2 infection: 77% (95%CI 9–94%) in the one-Ad26.COV2.S dose group and 52% (95%CI 13-73%) in the two-dose group. Severe COVID-19 was identified in 148 unboosted participants, and only one SHERPA participant with severe HIV-related immunosuppression. Of 11798 participants in the safety analysis, 271 (2.3%) reported a reactogenicity event or unsolicited AE, more among those with prior SARS-CoV-2 infections (adjusted odds ratio [aOR] 2.03, 95%CI 1.59-2.59) and less among people living with HIV (PLWH) (aOR 0.49, 95%CI 0.34-0.69). No related serious AEs were reported. In an immunogenicity sub-study, mRNA-1273 increased antibody functions and T-cell responses 4 weeks after boosting regardless of the number of prior Ad26.COV2.S doses, or HIV status, and generated Omicron spike-specific cross-reactive responses. mRNA-1273 boosters after one or two Ad26.COV2.S doses were well-tolerated, safe and effective against Omicron SARS-CoV-2 infections among HCWs and PLWH.

Trial Registration

The SHERPA study is registered in the Pan African Clinical Trials Registry (PACTR): PACTR202310615330649 and the South African National Clinical Trial Registry (SANCTR): DOH-27-052022-5778.